<DOC>
	<DOCNO>NCT02531841</DOCNO>
	<brief_summary>In presently plan multicentre Phase III trial two therapy compare : Patients randomize intensified induction treatment 4 cycle rituximab , methotrexate , cytarabine thiotepa ( MATRix ) first-line high-dose chemotherapy conventional consolidate therapy 2 cycle conventional chemotherapy R-DeVIC ( rituximab , dexamethasone , etoposide , ifosfamide , carboplatin ) .</brief_summary>
	<brief_title>High-dose Chemotherapy ASCT Consolidating Conventional Chemotherapy Primary CNS Lymphoma</brief_title>
	<detailed_description>Trial purpose rationale Primary central nervous system lymphoma ( PCNSL ) highly aggressive disease rise incidence past 30 year . Similar hematological disease , rationale consolidation PCNSL elimination minimal residual disease . The efficacy WBRT , current standard consolidation HD-MTX-based systemic treatment , compare HDT-ASCT ongoing IELSG-32 trial . High-dose chemotherapy carmustine busulfan thiotepa follow autologous stem cell transplantation show feasible highly effective newly diagnose eligible patient , also salvage situation . The question aim answer whether HDT-ASCT superior conventional therapy consolidation intensify immunochemotherapy newly diagnose PCNSL . Rationale study : Based previously obtain good result treatment recurrent refractory PCNSL DeVIC protocol choose conventional consolidation treatment . This protocol , originally design salvage protocol aggressive NHL , cross blood-brain barrier consist multidrug resistant unrelated agent . Treatment plan procedure Interventions Induction treatment 4 cycle ( every 3 week ) , stem-cell harvest 2nd cycle : - Rituximab 375 mg/m²/d i.v . ( 0,5 ) - Methotrexate 3,5 g/m² i.v . ( d1 ) - Cytarabine 2 x 2 g/m²/d i.v . ( d2-3 ) - Thiotepa 30 mg/m² i.v . ( d4 ) Patients PD two cycle , SD/PD four cycle induction therapy insufficient stem-cell harvest three cycle ineligible randomization . Consolidation Arm A 2 cycle R-DeVIC ( every 3 week ) : - Rituximab 375 mg/m²/d i.v . ( d0 ) - Dexamethasone 40 mg/d i.v . ( d1-3 ) - Etoposide 100 mg/m²/d i.v . ( d1-3 ) - Ifosfamide 1500 mg/m²/d i.v . ( d1-3 ) - Carboplatin 300 mg/m² i.v . ( d1 ) Consolidation Arm B High-dose chemotherapy ( HDT-ASCT ) : - Carmustine* 400 mg/m² i.v . ( d-6 ) - Thiotepa 2 x 5 mg/kg/d i.v . ( d-5- ( -4 ) ) - Autologous Stem Cell Transplantation ( d0 ) * carmustine available investigation site , busulfan administer instead : - Busulfan 3,2 mg/kg/d ( d-8- ( -7 ) ) - Thiotepa 2 x 5 mg/kg/d i.v . ( d-5- ( -4 ) ) - Autologous Stem Cell Transplantation ( d0 )</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Isophosphamide mustard</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<mesh_term>Carmustine</mesh_term>
	<mesh_term>Thiotepa</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<criteria>1 . Immunocompetent patient newlydiagnosed primary central nervous system Bcell lymphoma 2 . Age 1865 year irrespective ECOG 6670 year ( ECOG Performance Status ≤2 ) 3 . Histologically cytologically assess diagnosis Bcell lymphoma local pathologist . 4 . Diagnostic sample obtain stereotactic surgical biopsy , CSF cytology examination vitrectomy 5 . Disease exclusively locate CNS 6 . At least one measurable lesion 7 . Previously untreated patient ( previous ongoing steroid treatment admit ) 8 . Sexually active patient childbearing potential agree take adequate contraceptive measure study participation 9 . Written inform consent obtain accord international guideline local law patient authorized legal representative case patient temporarily legally competent due disease ADDITIONAL RANDOMIZATION CRITERIA 1 . Sufficient stem cell harvest ( ≥ 5 x 106 CD34+ cells/kg body weight ) 2 . Complete remission , unconfirmed complete remission partial remission 3 . Central pathology result confirm local result 1 . Congenital acquire immunodeficiency 2 . Systemic lymphoma manifestation ( outside CNS ) 3 . Isolated ocular lymphoma without manifestation brain parenchyma spinal cord 4 . Previous concurrent malignancy exception surgically cure carcinoma insitu cervix , carcinoma skin kind cancer without evidence disease least 5 year 5 . Previous NonHodgkin lymphoma time 6 . Inadequate bone marrow ( platelet count decrease ≥CTC grade 1 , anemia ≥CTC grade 1 , neutrophil count decrease ≥CTC grade 1 ) , renal ( creatinine clearance &lt; 60 ml/min ) , cardiac ( ejection fraction decrease ≥CTC grade 2 ) , hepatic function ( blood bilirubin increase ≥CTC grade 2 , alanine aminotransferase increase ≥CTC grade 2 , aspartate aminotransferase increase ≥CTC grade 2 gammaGT increase ≥CTC grade 2 ) 7 . HBsAg , antiHBc HCV positivity 8 . HIV infection , previous organ transplantation clinical evident form immunodeficiency 9 . Concurrent treatment experimental drug participation clinical trial within last thirty day start study 10 . Symptomatic coronary artery disease , cardiac arrhythmia uncontrolled medication myocardial infarction within last 6 month ( New York Heart Association Class III IV heart disease ) 11 . Severe noncompensated pulmonary disease ( IVC &lt; 55 % , DLCO &lt; 40 % ) 12 . Third space fluid accumulation &gt; 500 ml 13 . Hypersensitivity study treatment component formulation 14 . Taking medication likely cause interaction study medication 15 . Known persistent abuse medication , drug alcohol 16 . Patient without legal capacity unable understand nature , significance consequence study without designated legal representative 17 . Persons relationship dependency/employment sponsor and/ investigator 18 . Any familial , sociological geographical condition potentially hamper compliance study protocol followup schedule 19 . Concurrent ( plan ) pregnancy lactation 20 . Fertile patient refuse use safe contraceptive method study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 2015</verification_date>
</DOC>